{
    "id": "620580afc9dfcb9c0900002f",
    "question": "Does daily atemoya juice intake change the pharmacokinetics of CYP1A2 substrates?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "To answer this question, let's analyze the provided documents step by step. Step 1: Understand the role of atemoya juice in the context of CYP enzymes. There is no direct mention of \"atemoya juice\" in the provided documents. However, we can infer that the question might be referring to \"grapefruit juice,\" which is a well-known inhibitor of CYP3A4, a specific CYP enzyme. Step 2: Review the effects of grapefruit juice on CYP3A4. Grapefruit juice is known to inhibit the activity of CYP3A4, which can lead to increased levels of drugs that are substrates of this enzyme. However, there is no mention of CYP1A2 in the provided documents. Step 3: Review the effects of grapefruit juice on CYP1A2 substrates. The documents do not provide information on the effects of grapefruit juice on CYP1A2 substrates. CYP1A2 is a different CYP enzyme, and grapefruit juice is not mentioned as an inhibitor or inducer of this enzyme. Step 4: Consider the possibility of a typographical error in the question. It is possible that the question contains a typographical error, and \"atemoya\" is intended to refer to \"grapefruit.\" Conclusion: Given the lack of information on the effects of atemoya juice (which we assume might be a typographical error for grapefruit juice) on CYP1A2 substrates, we cannot accurately answer the question based on the provided documents. However, if we assume the question refers to grapefruit juice, the answer would be that grapefruit juice does not affect the pharmacokinetics of CYP1A2 substrates, as there is no information on its effects on this enzyme. However, since the question specifically asks about CYP1A2 substrates and grapefruit juice's effects on this enzyme are not mentioned, the most accurate answer would be based on the assumption that the question contains an error. Given the available options, the best answer would be: {\"step_by_step_thinking\": \"Based on the assumption that the question contains a typographical error and refers to grapefruit juice, which is not known to affect CYP1A2 substrates. However, the correct answer cannot be determined with the provided information.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_440",
            "title": "Pharmacology_Katzung",
            "content": "Diet and environmental factors contribute to individual variations in drug metabolism. Charcoal-broiled foods and cruciferous vegetables are known to induce CYP1A enzymes, whereas grapefruit juice is known to inhibit the CYP3A metabolism of co-administered drug substrates (Table 4\u20132; also see below). Cigarette smokers metabolize some drugs more rapidly than nonsmokers because of enzyme induction (see previous section). Industrial workers exposed to some pesticides metabolize certain drugs more rapidly than unexposed individuals. Such differences make it difficult to determine effective and safe doses of drugs that have narrow therapeutic indices."
        },
        {
            "id": "Biochemistry_Lippincott_542",
            "title": "Biochemistry_Lippinco",
            "content": "3.3. An individual who has recently been prescribed a drug (atorvastatin) to lower cholesterol levels is advised to limit consumption of grapefruit juice, because high intake of the juice reportedly results in an increased level of the drug in the blood, increasing the risk of side effects. Atorvastatin is a substrate for the cytochrome P450 enzyme CYP3A4, and grapefruit juice inhibits the enzyme. Which statement concerning CYP enzymes is most likely correct? They: A. accept electrons from reduced nicotinamide adenine dinucleotide. B. catalyze the hydroxylation of hydrophobic molecules. C. differ from nitric oxide synthase in that they contain heme. D. function in association with an oxidase."
        },
        {
            "id": "Pharmacology_Katzung_4036",
            "title": "Pharmacology_Katzung",
            "content": "2. Pharmacokinetics: The recommended dose of tofacitinib in the treatment of RA is 5 mg twice daily; there is a clear trend to increased response (and increased toxicity) at double this dose. In 2016, the FDA approved extended-release (XR) tofacitinib citrate 11 mg tablets for once-daily treatment. Tofacitinib has an absolute oral bioavailability of 74%, high-fat meals do not affect the AUC, and the elimination half-life is about 3 hours. Metabolism (of 70%) occurs in the liver, mainly by CYP3A4 and to a lesser extent by CYP2C19. The remaining 30% is excreted unchanged by the kidneys. Patients taking CYP enzyme inhibitors and those with moderate hepatic or renal impairment require dose reduction to 5 mg once daily. It should not be given to patients with severe hepatic disease. 3."
        },
        {
            "id": "Pharmacology_Katzung_450",
            "title": "Pharmacology_Katzung",
            "content": "Impaired metabolism may also result if a simultaneously administered drug irreversibly inactivates a common metabolizing enzyme. These inhibitors, in the course of their metabolism by cytochrome P450, inactivate the enzyme and result in impairment of their own metabolism and that of other cosubstrates. This is the case of the furanocoumarins in grapefruit juice, eg, 6\u2032,7\u2032-dihydroxybergamottin and bergamottin, which inactivate CYP3A4 in the intestinal mucosa and consequently enhance its proteolytic degradation. This impairment of intestinal first-pass CYP3A4-dependent metabolism significantly enhances the bioavailability of drugs such as ergotamine, felodipine, nifedipine, terfenadine, verapamil, ethinylestradiol, lovastatin, saquinavir, and cyclosporine A and is associated with clinically relevant DDIs and food-drug interactions. The list of drugs subject to DDIs involving grapefruit juice is extensive and includes many drugs with a very narrow therapeutic index and a high potential"
        },
        {
            "id": "Pharmacology_Katzung_460",
            "title": "Pharmacology_Katzung",
            "content": "Nelson DR et al: Updated human P450 sequences. http://drnelson.uthsc.edu/ cytochromeP450.html. Pirmohamed M: Drug-grapefruit juice interactions: Two mechanisms are clear but individual responses vary. Br Med J 2013;346:f1. Posadzki P, Watson L, Ernst E: Herb-drug interactions: An overview of systematic reviews. Br J Clin Pharmacol 2013;75:603. Rahimi R, Abdollahi M: An update on the ability of St. John\u2019s wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol 2012;8:691. Rieder MJ et al: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285. Russo E et al: Hypericum perforatum: Pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother Res 2014;28:643. Saitta KS et al: Bacterial beta-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: Mode of action and pharmacokinetics. Xenobiotica 2014;44:28."
        },
        {
            "id": "Pharmacology_Katzung_447",
            "title": "Pharmacology_Katzung",
            "content": "Conversely, simultaneous administration of two or more drugs may result in impaired elimination of the more slowly metabolized drug and prolongation or potentiation of its pharmacologic effects (Table 4\u20136). Both competitive substrate inhibition and irreversible substrate-mediated enzyme inactivation may augment plasma drug levels and lead to toxic effects from drugs with narrow therapeutic indices. Indeed, such acute interactions of terfenadine (a second-generation antihistamine) with a CYP3A4 substrate-inhibitor (ketoconazole, erythromycin, or grapefruit juice) resulted in fatal cardiac arrhythmias (torsades de pointes) requiring its withdrawal from the market. Similar DDIs with CYP3A4 substrate-inhibitors (such as the antibiotics erythromycin and clarithromycin, the antidepressant nefazodone, the antifungals itraconazole and ketoconazole, and the HIV protease inhibitors indinavir and ritonavir) and consequent cardiotoxicity"
        },
        {
            "id": "InternalMed_Harrison_421",
            "title": "InternalMed_Harrison",
            "content": "Grapefruit (but not orange) juice inhibits CYP3A, especially at inhibition may increase the risk of adverse effects (e.g., cyclosporine, fruit juice. CYP2D6 is markedly inhibited by quinidine, a number of neurolep tic drugs (chlorpromazine and haloperidol), and the SSRIs fluoxetine and paroxetine. The clinical consequences of fluoxetine\u2019s interaction with CYP2D6 substrates may not be apparent for weeks after the drug is started, because of its very long half-life and slow generation of a CYP2D6-inhibiting metabolite. 6-Mercaptopurine is metabolized not only by TPMT but also by xanthine oxidase. When allopurinol, an inhibitor of xanthine oxidase, is administered with standard doses of azathioprine or 6-mercaptopu rine, life-threatening toxicity (bone marrow suppression) can result."
        },
        {
            "id": "InternalMed_Harrison_31709",
            "title": "InternalMed_Harrison",
            "content": "With the exception of citalopram and escitalopram, each of the SSRIs may inhibit one or more cytochrome P450 enzymes. Depending on the specific isoenzyme involved, the metabolism of a number of concomitantly administered medications can be dramatically affected. Fluoxetine and paroxetine, for example, by inhibiting 2D6, can cause dramatic increases in the blood level of type 1C antiarrhythmics, whereas sertraline, by acting on 3A4, may alter blood levels of carbamazepine or digoxin. Depending on drug specificity for a particular CYP enzyme for its own metabolism, concomitant medications or dietary factors, such as grapefruit juice, may in turn affect the efficacy or toxicity of the SSRI."
        },
        {
            "id": "InternalMed_Harrison_16281",
            "title": "InternalMed_Harrison",
            "content": "Halofantrine exhibits erratic bioavailability, but its absorption is significantly enhanced when it is taken with a fatty meal. The elimination half-life of halofantrine is 1\u20132 days; it is excreted mainly in feces. Halofantrine is metabolized into N-debutyl-halofantrine by the cytochrome P450 enzyme CYP3A4. Grapefruit juice should be avoided during treatment because it increases both halofantrine\u2019s bioavailability and halofantrine-induced QT interval prolongation by inhibiting CYP3A4 at the enterocyte level."
        },
        {
            "id": "Pharmacology_Katzung_418",
            "title": "Pharmacology_Katzung",
            "content": "FIGURE 4\u20136 Genetic polymorphism in debrisoquin 4-hydroxylation by CYP2D6 in a Caucasian population. The semilog frequency distribution histogram of the metabolic ratio (MR; defined as percent of dose excreted as unchanged debrisoquin divided by the percent of dose excreted as 4-hydroxydebrisoquin metabolite) in the 8-hour urine collected after oral ingestion of 12.8 mg debrisoquin sulfate (equivalent to 10 mg free debrisoquin base). Individuals with MR values >12.6 were phenotyped as poor metabolizers (PM, red bars), and those with MR values <12.6 but >0.2 were designated as extensive metabolizers (EM, blue bars). Those with MR values <0.2were designated as ultrarapid metabolizers (URM, green bars) based on the MR values (0.01\u20130.1) of individuals with documented multiple copies of CYP2D6 allelic variants resulting from inherited amplification of this gene. (Data from Woolhouse et al: Debrisoquin hydroxylation polymorphism among Ghanians and Caucasians. Clin Pharmacol Ther"
        },
        {
            "id": "InternalMed_Harrison_420",
            "title": "InternalMed_Harrison",
            "content": "Decreased concentration and effects of methadone, dabigatran Increased effect of many \u03b2 blockers Decreased codeine effect; possible decreased tamoxifen effect Increased concentration and effects of phenytoin Increased concentration and toxicity of some HMG-CoA reductase inhibitors cyclosporine, cisapride, terfenadine (now withdrawn) Increased concentration and effects of indinavir (with ritonavir) Decreased clearance and dose requirement for cyclosporine (with calcium channel blockers) Azathioprine and 6-mercaptopurine toxicity Decreased clearance (risk of toxicity) for quinidine Rhabdomyolysis when co-prescribed with some HMG-CoA reductase inhibitors Risk of toxicity with P-glycoprotein substrates (e.g., digoxin, dabigatran) Increased risk of methotrexate toxicity with salicylates Grapefruit (but not orange) juice inhibits CYP3A, especially at inhibition may increase the risk of adverse effects (e.g., cyclosporine, fruit juice."
        },
        {
            "id": "Pharmacology_Katzung_451",
            "title": "Pharmacology_Katzung",
            "content": "relevant DDIs and food-drug interactions. The list of drugs subject to DDIs involving grapefruit juice is extensive and includes many drugs with a very narrow therapeutic index and a high potential for lethal adverse reactions. However, it must be borne in mind that not all commercially available grapefruit juices are equally potent, as the CYP3A4 inactivation potency is totally dependent on the amount of furanocoumarins extracted into the juice from the zest (highest), pith, and pulp of the grapefruit. Furthermore, recovery from these interactions is dependent on CYP3A4 resynthesis and thus may be slow."
        },
        {
            "id": "InternalMed_Harrison_389",
            "title": "InternalMed_Harrison",
            "content": "FIgURE 5-6 A. CYP2D6 metabolic activity was assessed in 290 subjects by administration of a test dose of a probe substrate and measurement of urinary formation of the CYP2D6-generated metabolite. The heavy arrow indicates a clear antimode, separating poor metabolizer subjects (PMs, red), with two loss-of-function CYP2D6 alleles, indicated by the intron-exon structures below the chart. Individuals with one or two functional alleles are grouped together as extensive metabolizers (EMs, green). Also shown are ultra-rapid metabolizers (UMs), with 2\u201312 functional copies of the gene (gray), displaying the greatest enzyme activity. (Adapted from M-L Dahl et al: J Pharmacol Exp Ther 274:516, 1995.) B. These simulations show the predicted effects of CYP2D6 genotype on disposition of a substrate drug. With a single dose (left), there is an inverse \u201cgene-dose\u201d relationship between the number of active alleles and the areas under the time-concentration curves (smallest in UM subjects; highest in"
        },
        {
            "id": "Pharmacology_Katzung_93",
            "title": "Pharmacology_Katzung",
            "content": "Known and unknown diseases and risk factors (including lifestyles of subjects) may influence the results of a clinical study. For example, some diseases alter the pharmacokinetics of drugs (see Chapters 3 through 5). Other drugs and some foods alter the pharmacokinetics of many drugs. Concentrations of blood or tissue components being monitored as a measure of the effect of the new agent may be influenced by other diseases or other drugs. Attempts to avoid this hazard usually involve the crossover technique (when feasible) and proper selection and assignment of patients to each of the study groups. This requires obtaining accurate diagnostic tests and medical and pharmacologic histories (including use of recreational drugs, over-the-counter drugs, and \u201csupplements\u201d) and the use of statistically valid methods of randomization in assigning subjects to particular study groups. There is growing interest in analyzing genetic variations as part of the trial that may influence whether a"
        },
        {
            "id": "Pharmacology_Katzung_356",
            "title": "Pharmacology_Katzung",
            "content": "Timing of Samples for Concentration Measurement Information about the rate and extent of drug absorption in a particular patient is rarely of great clinical importance. Absorption usually occurs during the first 2 hours after a drug dose and varies according to food intake, posture, and activity. Therefore, it is important to avoid drawing blood until absorption is complete (about 2 hours after an oral dose). Attempts to measure peak concentrations early after oral dosing are usually unsuccessful and compromise the validity of the measurement, because one cannot be certain that absorption is complete. Plasma Protein Binding: Is It Important?"
        },
        {
            "id": "Pharmacology_Katzung_3331",
            "title": "Pharmacology_Katzung",
            "content": "A. Selective Serotonin Reuptake Inhibitors The most common interactions with SSRIs are pharmacokinetic interactions. For example, paroxetine and fluoxetine are potent CYP2D6 inhibitors (Table 30\u20134). Thus, administration with 2D6 substrates such as TCAs can lead to dramatic and sometimes unpredictable elevations in the tricyclic drug concentration. The result may be toxicity from the TCA. Similarly, fluvoxamine, a CYP3A4 inhibitor, may elevate the levels of concurrently administered substrates for this enzyme such as diltiazem and induce bradycardia or hypotension. Other SSRIs, such as citalopram and escitalopram, are relatively free of pharmacokinetic interactions. The most serious interaction with the SSRIs are pharmacodynamic interactions with MAOIs that produce a serotonin syndrome (see below). B. Selective Serotonin-Norepinephrine Reuptake Inhibitors and Tricyclic Antidepressants"
        },
        {
            "id": "Pharmacology_Katzung_425",
            "title": "Pharmacology_Katzung",
            "content": "Allelic variants of CYP3A4 have also been reported, but their contribution to the well-known interindividual variability in drug metabolism apparently is limited. On the other hand, the expression of CYP3A5, another human liver isoform, is markedly polymorphic, ranging from 0% to 100% of the total hepatic CYP3A content. This CYP3A5 protein polymorphism is now known to result from a single nucleotide polymorphism (SNP) within intron 3, which enables normally spliced CYP3A5 transcripts in 5% of Caucasians, 29% of Japanese, 27% of Chinese, 30% of Koreans, and 73% of African Americans. Thus, it can significantly contribute to inter-individual differences in the metabolism of preferential CYP3A5 substrates such as midazolam. Two other CYP3A5 allelic variants that result in a PM phenotype are also known."
        },
        {
            "id": "Pharmacology_Katzung_459",
            "title": "Pharmacology_Katzung",
            "content": "Kuehl P et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383. Lindenbaum J et al: Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N Engl J Med 1981;305:789. Lown KS et al: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545. Meyer UA: Pharmacogenetics\u2014Five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004;5:669. Morgan ET et al: Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008;36:205. Nelson DR et al: The P450 superfamily: Update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 1996;6:1. Nelson DR et al: Updated human P450 sequences. http://drnelson.uthsc.edu/ cytochromeP450.html."
        },
        {
            "id": "InternalMed_Harrison_364",
            "title": "InternalMed_Harrison",
            "content": "When plasma concentrations of active drug depend exclusively on a single metabolic pathway, any condition that inhibits that pathway (be it disease-related, genetic, or due to a drug interaction) can lead to dramatic changes in drug concentrations and marked variability in drug action. This problem of high-risk pharmacokinetics is especially pronounced in two settings. First, variability in bioactivation of a prodrug can lead to striking variability in drug action; examples include decreased CYP2D6 activity, which prevents analgesia by codeine, and decreased CYP2C19 activity, which reduces the antiplatelet effects of clopidogrel. The second setting is drug elimination that relies on"
        },
        {
            "id": "Pharmacology_Katzung_3014",
            "title": "Pharmacology_Katzung",
            "content": "Another nonergoline derivative, ropinirole (now available in a generic preparation) is a relatively pure D2 receptor agonist that is effective as monotherapy in patients with mild disease and as a means of smoothing the response to levodopa in patients with more advanced disease and response fluctuations. It is introduced at 0.25 mg three times daily, and the total daily dose is then increased by 0.75 mg at weekly intervals until the fourth week and by 1.5 mg thereafter. In most instances, a dosage between 2 and 8 mg three times daily is necessary. Ropinirole is metabolized by CYP1A2; other drugs metabolized by this isoform may significantly reduce its clearance. A prolonged-release preparation taken once daily is available."
        },
        {
            "id": "Pharmacology_Katzung_3281",
            "title": "Pharmacology_Katzung",
            "content": "Mirtazapine is demethylated followed by hydroxylation and glucuronide conjugation. Several CYP isozymes are involved in the metabolism of mirtazapine, including 2D6, 3A4, and 1A2. The half-life of mirtazapine is 20\u201340 hours, and it is usually dosed once in the evening because of its sedating effects. Vilazodone is well absorbed (Table 30\u20131), and absorption is increased when it is given with a fatty meal. It is extensively metabolized by CYP3A4 with minor contributions by CYP2C19 and CYP2D6. Only 1% of vilazodone is excreted unchanged in the urine. E. Monoamine Oxidase Inhibitors The different MAOIs are metabolized via different pathways but tend to have extensive first-pass effects that may substantially decrease bioavailability. Tranylcypromine is ring hydroxylated and N-acetylated, whereas acetylation appears to be a minor pathway for phenelzine. Selegiline is N-demethylated and then hydroxylated. The MAOIs are well absorbed from the gastrointestinal tract."
        },
        {
            "id": "InternalMed_Harrison_365",
            "title": "InternalMed_Harrison",
            "content": "Chapter 5 Principles of Clinical Pharmacology a single pathway. In this case, inhibition of the elimination pathway by genetic variants or by administration of inhibiting drugs leads to marked elevation of drug concentration and, for drugs with a narrow therapeutic window, an increased likelihood of dose-related toxicity. Individuals with loss-of-function alleles in CYP2C9, responsible for metabolism of the active S-enantiomer of warfarin, appear to be at increased risk for bleeding. When drugs undergo elimination by multi-ple-drug metabolizing or excretory pathways, absence of one pathway (due to a genetic variant or drug interaction) is much less likely to have a large impact on drug concentrations or drug actions."
        },
        {
            "id": "Pharmacology_Katzung_448",
            "title": "Pharmacology_Katzung",
            "content": "Troleandomycin Theophylline, methylprednisolone 1While some inhibitors are selective for a given P450 enzyme, others are more general and can inhibit several P450s concurrently. 2Active components in grapefruit juice include furanocoumarins such as 6\u2032, 7\u2032-dihydroxybergamottin (which inactivates both intestinal and liver CYP3A4) as well as other unknown components that inhibit P-glycoprotein-mediated intestinal drug efflux and consequently further enhance the bioavailability of certain drugs such as cyclosporine. For a more comprehensive list of drugs whose metabolism is inhibited by grapefruit juice furanocoumarins, see Bailey et al, 2013."
        },
        {
            "id": "Pharmacology_Katzung_412",
            "title": "Pharmacology_Katzung",
            "content": "The dose and frequency of administration required to achieve effective therapeutic blood and tissue levels vary in different patients because of individual differences in drug distribution and rates of drug metabolism and elimination. These differences are determined by genetic factors as well as nongenetic variables, such as commensal gut microbiota, age, sex, liver size, liver function, circadian rhythm, body temperature, and nutritional and environmental factors such as concomitant exposure to inducers or inhibitors of drug metabolism. The discussion that follows summarizes the most important of these variables. Individual differences in metabolic rate depend on the nature of the drug itself. Thus, within the same population, steady-state plasma levels may reflect a 30-fold variation in the metabolism of one drug and only a twofold variation in the metabolism of another."
        },
        {
            "id": "InternalMed_Harrison_349",
            "title": "InternalMed_Harrison",
            "content": "Note: A listing of CYP substrates, inhibitors, and inducers is maintained at http://medicine .iupui.edu/flockhart/table.htm. that accomplish phase II reactions include glucuronyl-, acetyl-, sulfo-, and methyltransferases. Drug metabolites may exert important pharmacologic activity, as discussed further below. Clinical Implications of Altered Bioavailability Some drugs undergo near-complete presystemic metabolism and, thus, cannot be administered orally. Nitroglycerin cannot be used orally because it is completely extracted prior to reaching the systemic circulation. The drug is, therefore, used by the sublingual or transdermal routes, which bypass presystemic metabolism."
        },
        {
            "id": "Pharmacology_Katzung_3790",
            "title": "Pharmacology_Katzung",
            "content": "Apixaban has an oral bioavailability of 50% and prolonged absorption, resulting in a half-life of 12 hours with repeat dosing. The drug is a substrate of the cytochrome P450 system and P-glycoprotein and is excreted in the urine and feces. As with rivaroxaban, drugs inhibiting both CYP3A4 and P-glycoprotein, as well as impairment of renal or hepatic function, result in increased drug effect. Edoxaban is a once-daily Xa inhibitor with a 62% oral bioavailability. Peak drug concentrations occur 1\u20132 hours after dosage and are not affected by food. The drug half-life is 10\u201314 hours. Edoxaban does not induce CYP450 enzymes. No dose reduction is required with concurrent use of P-glycoprotein inhibitors. Edoxaban is primarily excreted unchanged in the urine."
        },
        {
            "id": "InternalMed_Harrison_418",
            "title": "InternalMed_Harrison",
            "content": "Amiodarone Inhibitor of many CYPs and of P-glycoprotein Gemfibrozil (and other fibrates) CYP3A inhibition Quinidine P-glycoprotein inhibition Amiodarone Verapamil Cyclosporine Itraconazole Erythromycin Phenylbutazone Inhibition of renal tubular transport Probenecid Salicylates erythromycin and some other macrolide antibiotics (clarithromycin but not azithromycin), ketoconazole and other azole antifungals, the antiretroviral agent ritonavir, and high concentrations of grapefruit juice (Table 5-3). The consequences of such interactions will depend on the drug whose elimination is being inhibited (see \u201cThe Concept of High-Risk Pharmacokinetics,\u201d above). Examples include CYP3A inhibitors increasing the risk of cyclosporine toxicity or of rhabdomyolysis with some HMG-CoA reductase inhibitors (lovastatin, simvastatin, atorvastatin, but not pravastatin), and P-glycoprotein inhibitors increasing the risk of toxicity with digoxin therapy or of bleeding with the thrombin inhibitor dabigatran."
        },
        {
            "id": "InternalMed_Harrison_31786",
            "title": "InternalMed_Harrison",
            "content": "Repeated use of alcohol contributes to acquired tolerance, a phenomenon involving at least three compensatory mechanisms. (1) After 1\u20132 weeks of daily drinking, metabolic or pharmacokinetic tolerance can be seen, with up to 30% increases in the rate of hepatic ethanol metabolism. This alteration disappears almost as rapidly as it develops. (2) Cellular or pharmacodynamic tolerance develops through neurochemical changes that maintain relatively normal physiologic functioning despite the presence of alcohol. Subsequent decreases in blood levels contribute to symptoms of withdrawal. (3) Individuals learn to adapt their behavior so that they can function better than expected under influence of the drug (learned or behavioral tolerance). Blood Level, g/dL Usual Effect 0.02 Decreased inhibitions, a slight feeling of intoxication 0.08 0.20 Obvious slurred speech, motor incoordination, irritability, and poor judgment 0.30 Light coma and depressed vital signs 0.40 Death"
        },
        {
            "id": "InternalMed_Harrison_22557",
            "title": "InternalMed_Harrison",
            "content": "PPIs. If PPIs are to be given, some have recommended that there be a 12-h separation between administration of the PPI and clopidogrel to minimize competition of the two agents with the involved cyto chrome P450. One option is to give the PPI 30 min before breakfast and the clopidogrel at bedtime. Insufficient data are available to firmly recommend one PPI over another. Patients 65 years of age or older have a higher risk for some of the long-term side effects of PPIs highlighted above, in part due to the higher prevalence of concomitant chronic diseases. It is therefore important to carefully select individuals, especially among the elderly, who need long-term PPI therapy and discontinue it in those individuals who do not need it."
        },
        {
            "id": "Biochemistry_Lippincott_1253",
            "title": "Biochemistry_Lippinco",
            "content": "4. Tolerable upper intake level: The highest average daily nutrient intake level that is likely to pose no risk of adverse health effects to almost all individuals in the general population is the Tolerable Upper Intake Level (UL, or TUL). As intake increases above the UL, the potential risk of adverse effects may increase. The UL is useful because of the increased availability of fortified foods and the increased use of dietary supplements. For some nutrients, there may be insufficient data on which to develop a UL. B. Using the dietary reference intakes"
        },
        {
            "id": "Pharmacology_Katzung_2398",
            "title": "Pharmacology_Katzung",
            "content": "H. Increased Risk of Cancer Chronic alcohol use increases the risk for cancer of the mouth, pharynx, larynx, esophagus, and liver. Evidence also points to a small increase in the risk of breast cancer in women. A threshold level for alcohol consumption as it relates to cancer has not been determined. Alcohol itself does not appear to be a carcinogen in most test systems. However, its primary metabolite, acetaldehyde, can damage DNA, as can the reactive oxygen species produced by increased cytochrome P450 activity. Other factors implicated in the link between alcohol and cancer include changes in folate metabolism and the growth-promoting effects of chronic inflammation. Interactions between ethanol and other drugs can have important clinical effects resulting from alterations in the pharmacokinetics or pharmacodynamics of the second drug."
        },
        {
            "id": "Pharmacology_Katzung_1672",
            "title": "Pharmacology_Katzung",
            "content": "terfenadine and astemizole should be considered to be contraindicated in patients taking ketoconazole, itraconazole, or macrolides and in patients with liver disease. Grapefruit juice also inhibits CYP3A4 and has been shown to increase blood levels of terfenadine significantly."
        }
    ],
    "scores": [
        0.03504617012223871,
        0.028276556469206245,
        0.02666285690732599,
        0.026564868562132582,
        0.023038378416062464,
        0.02294121076302384,
        0.022105263157894735,
        0.0220995670995671,
        0.018883049790683174,
        0.01793758043758044,
        0.01780392156862745,
        0.017564043564963952,
        0.016825733474726053,
        0.016421024295040044,
        0.016328978938949613,
        0.015716374269005847,
        0.015517241379310345,
        0.015070028011204481,
        0.01486949080017116,
        0.014664664664664664,
        0.014288559195459525,
        0.014134452102687045,
        0.014044674527849679,
        0.013877207737594618,
        0.013606071825249907,
        0.013571954361428044,
        0.013338668800853675,
        0.012884248902145994,
        0.012766474831806759,
        0.012475709288767976,
        0.01236103259845487,
        0.011733586543678783
    ]
}